Peptides in 2TM · Lixisenatide
Episode 03 · 2 minutes · English
Lixisenatide: timing the signal
From Zealand Pharma’s Danish development work to the response after a meal. Follow lixisenatide through GLP-1 receptor signaling, gastric emptying, and its combination with insulin glargine.
English narration and captions. Caption timing is approximate. Translated subtitles are not yet available for this episode.
Published .
Behind the film: Lixisenatide references & context
Zealand Pharma’s company reporting attributes the invention of lixisenatide to Zealand and describes its global licensing to Sanofi. This is company reporting, not an independent historical assessment or attribution to an individual scientist.
Slower gastric emptying changes how quickly meal-derived glucose reaches circulation. Insulin release is glucose-dependent. The molecular artwork, tissue cross-section, and moving signal symbols are conceptual; they are not microscopy, validated molecular structures, or quantitative physiological models.
Lyxumia received EU authorization in 2013 and Adlyxin received U.S. approval in 2016. These are historical approvals, not claims of current local supply. Lyxumia’s standalone EU authorization was withdrawn on December 18, 2025 at the manufacturer’s request for commercial reasons. Insulin glargine/lixisenatide combinations, including Suliqua and Soliqua, have separate authorizations. Availability and prescribing information vary by jurisdiction.
The film includes selected safety information, not complete prescribing guidance. Source verification is distinct from scientific assessment or personal human review. No independent human scientific review or endorsement is claimed.
- Zealand Pharma annual report, 2015: development attribution and licensing; company source.
- EMA: Lyxumia: EU authorization and withdrawal.
- FDA: original Adlyxin approval letter, July 27, 2016.
- FDA: archived Adlyxin prescribing information, 2023: mechanism, pharmacokinetics, and selected safety information; not represented as the latest local label.
- EMA: Suliqua and DailyMed: Soliqua 100/33: insulin glargine/lixisenatide combination product information.
Sanofi photograph: Chris Rycroft, Sanofi-Genzyme building, Cambridge, Massachusetts, CC BY 2.0; cropped, shaded, animated, and titled. A contemporary company location, not the historical discovery laboratory.
Medical artwork: Stomach, Pancreas, and Gallbladder Unlabeled — NIDDK, NIH; cropped, background removed, animated, and accompanied by conceptual flow symbols. No NIH endorsement implied.
Zealand Pharma logo identifies the company; trademark rights remain with its owner. Logo source. Closing microscope and glassware photograph: Adobe Stock asset 278678145, licensed from its free collection; cropped, shaded, and animated. Illustrative laboratory equipment, not the actual lixisenatide research or manufacturing facility.
Production: synthetic narration and music, AI-generated conceptual molecular artwork, and locally created conceptual tissue and signaling animation. These visuals do not establish an exact lixisenatide conformation or manufacturing method.
Educational information, not medical advice. WPF does not sell peptides. Suggest a correction.
Read the English transcript — Lixisenatide
A meal sets a chain reaction in motion. Food moves through the stomach, glucose enters the bloodstream, and the body responds. Lixisenatide helps reshape that response.
Its story begins with Zealand Pharma in Denmark, where researchers developed the peptide before licensing it to Sanofi for further development and commercialization.
Lixisenatide activates the GLP-1 receptor, a biological switch involved in controlling blood sugar. After an injection beneath the skin, the medicine is absorbed into circulation.
One important effect is slowing the movement of food from the stomach into the intestine. That changes how quickly glucose from a meal reaches the bloodstream, helping reduce the rise in blood sugar after eating. In the pancreas, lixisenatide also supports insulin release when glucose is elevated and reduces glucagon secretion.
The medicine received European Union authorization as Lyxumia in 2013, followed by U.S. approval as Adlyxin in 2016, for adults with type 2 diabetes. Its story continued in combination with insulin glargine, under names including Suliqua and Soliqua. Basal insulin and lixisenatide bring complementary actions to glucose control.
But approval and availability are different things. Lyxumia’s standalone European authorization was withdrawn in December 2025 at the manufacturer’s request for commercial reasons. The combination has its own authorization.
Like every medicine, lixisenatide has limitations. Nausea and vomiting are common. Important warnings include pancreatitis, severe allergic reactions, and increased risk of low blood sugar when combined with insulin.
Lixisenatide shows how the timing of a biological signal can become part of a medicine’s design. Explore the evidence at World Peptide Foundation. Peptides in two. Every experience matters.